RA Capital Management and Sectoral Asset Management led a $115m Series C round in Evommune.

RA Capital Management and Sectoral Asset Management, venture capital firms, led a $115m Series C round in Evommune, a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, with participation from B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures and Allostery Investments LP, Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, SymBiosis and Verition Fund Management.